Abbott cuts sales reps amid "shifting resources"

Share this article:

Abbott laid off approximately 175 sales reps in the US, Dow Jones reported yesterday.

The company "shifted resources" within its US pharma business, and layoffs were not related to a specific brand, Scott Stoffel, an Abbott spokesperson, told MM&M. "[The layoffs] were largely due to some shifts made in geographical territories," said Stoffel, referring to sales rep assignment areas.

The layoffs follow the completion of Abbott's $6.2 billion acquisition of Solvay Pharmaceuticals in February. Abbott expects the Solvay deal to bring in an additional $2.9 billion in 2010 global sales, the company said in a February statement. Stoffel told Dow Jones that there were no plans for any additional sales force cuts.

Abbott announced on Tuesday that Certriad, a combination of AstraZeneca's Crestor and Abbott's Trilipix, received a complete response letter from the FDA, asking that the company provide additional information on the as yet unapproved cholesterol drug.

Separately, Abbott announced the submission of a new diagnostic test for FDA review. The test, if approved, would help identify patients at risk for acute kidney injury, and would represent the first test available in the US for the detection of neutrophil gelatinase-associated lipocalin.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...